-+ 0.00%
-+ 0.00%
-+ 0.00%

*Kira Out-Licenses KP-301, Long-Acting anti-C5a Monoclonal Antibody, and KP-402, Small Molecule C5a Receptor Antagonist, to Mirador Therapeutics, for $12 M

Dow Jones·07/16/2026 21:25:00

登录查看新闻详情